We are live on
!
Find out more
CIM
Contravisory Investment Management Portfolio holdings
AUM
$566M
1-Year Est. Return
42.93%
This Fund
S&P 500
This Quarter
Est. Return
+3.41%
1 Year Est. Return
+42.93%
3 Year Est. Return
+129.34%
5 Year Est. Return
+198.47%
10 Year Est. Return
+603.03%
AUM
$480M
AUM Growth
-$26.6M
(-5.3%)
Cap. Flow
-$35.6M
Cap. Flow
% of AUM
-7.41%
Top 10 Holdings %
Top 10 Hldgs %
32.85%
Holding
185
New
38
Increased
7
Reduced
35
Closed
37
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
GG
Goldcorp Inc
GG
|
+$12.4M |
| 2 |
International Flavors & Fragrances
IFF
|
+$12M |
| 3 |
Entergy
ETR
|
+$11.8M |
| 4 |
MJN
Mead Johnson Nutrition Company
MJN
|
+$11.5M |
| 5 |
Norfolk Southern
NSC
|
+$11.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
PARA
Paramount Global Class B
PARA
|
+$17.2M |
| 2 |
RTN
Raytheon Company
RTN
|
+$14M |
| 3 |
Mastercard
MA
|
+$14M |
| 4 |
IRF
INTL RECTIFIER CORP
IRF
|
+$13.1M |
| 5 |
CVG
Convergys
CVG
|
+$12.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.18% |
| 2 | Technology | 18.26% |
| 3 | Materials | 12.66% |
| 4 | Industrials | 9.96% |
| 5 | Energy | 6.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Gilead Sciences
GILD
$161B
| $24M | 5% |
225,060
-19,513
| -8% | -$1.91M |
|
2
Moody's
MCO
$81.7B
| $17.4M | 3.63% |
184,226
-13,486
| -7% | -$1.24M |
|
|
SNDK
3
DELISTED
SANDISK CORP
SNDK
| $15.9M | 3.32% |
162,695
-10,899
| -6% | -$1.07M |
|
4
Cintas
CTAS
$82.4B
| $14.9M | 3.1% |
841,968
-60,588
| -7% | -$987K |
|
|
X
5
DELISTED
US Steel
X
| $14.8M | 3.09% |
378,561
-24,677
| -6% | -$865K |
|
6
Amgen
AMGN
$203B
| $14.8M | 3.08% |
105,253
-6,918
| -6% | -$903K |
|
7
Halliburton
HAL
$27.9B
| $14.7M | 3.07% |
227,901
-17,086
| -7% | -$1.17M |
|
8
Humana
HUM
$46.7B
| $14M | 2.92% |
107,317
-7,767
| -7% | -$987K |
|
9
American International
AIG
$41.9B
| $13.6M | 2.84% |
252,257
-16,919
| -6% | -$924K |
|
10
CVS Health
CVS
$137B
| $13.5M | 2.81% |
169,228
-12,217
| -7% | -$963K |
|
11
Archer Daniels Midland
ADM
$41.4B
| $12.5M | 2.61% |
245,324
-15,425
| -6% | -$757K |
|
12
Ashland
ASH
$3.04B
| $12.5M | 2.61% |
246,026
-16,763
| -6% | -$873K |
|
|
HSP
13
DELISTED
HOSPIRA INC
HSP
| $12.5M | 2.61% |
240,701
-6,038
| -2% | -$321K |
|
14
Open Text
OTEX
$5.43B
| $12.5M | 2.61% |
451,902
-31,648
| -7% | -$845K |
|
15
Baidu
BIDU
$35.8B
| $12.4M | 2.59% |
56,977
-3,858
| -6% | -$816K |
|
|
16
Norfolk Southern
NSC
$78.8B
| $12.1M | 2.52% |
+108,473
| New | +$11.5M |
|
|
17
Entergy
ETR
$54.1B
| $12M | 2.51% |
+310,688
| New | +$11.8M |
|
18
Autoliv
ALV
$8.6B
| $11.8M | 2.47% |
178,892
-12,624
| -7% | -$928K |
|
|
MJN
19
DELISTED
Mead Johnson Nutrition Company
MJN
| $11.7M | 2.44% |
+121,782
| New | +$11.5M |
|
20
HP
HPQ
$23.5B
| $11.7M | 2.43% |
723,903
+707,155
| +4,222% | +$11.5M |
|
21
F5
FFIV
$22.1B
| $11.5M | 2.4% |
+96,905
| New | +$11.4M |
|
|
22
International Flavors & Fragrances
IFF
$19.4B
| $11.4M | 2.37% |
+118,788
| New | +$12M |
|
23
Merck
MRK
$324B
| $11.4M | 2.37% |
+201,117
| New | +$11.3M |
|
|
DD
24
DELISTED
Du Pont De Nemours E I
DD
| $11.1M | 2.31% |
162,214
-4,801
| -3% | -$302K |
|
25
Check Point Software Technologies
CHKP
$13.3B
| $10.9M | 2.27% |
157,470
-9,593
| -6% | -$653K |
|
Similar funds
FG
SAM
BCMLT
KJWM
PAM
PEP
OC
LC
Contravisory Investment Management's Q3 2014 Portfolio in Review
As of Q3 2014, Contravisory Investment Management held 185 positions worth $480M, down 5.3% from $506M the previous quarter. Its ten largest holdings account for 33% of the portfolio.
Contravisory Investment Management withdrew a net $35.6M in Q3 2014, closing 37 positions and reducing 35 holdings. Its most notable exit was Paramount Global Class B, an estimated $17.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 19% a quarter earlier, followed by Technology and Materials.
Against the trend, Contravisory Investment Management opened a new position in Goldcorp Inc worth $10.7M.
- Contravisory Investment Management's largest Q3 2014 buy was Goldcorp Inc: 463,011 shares worth $10.7M.
- Contravisory Investment Management added most to HP in Q3 2014, an estimated $11.5M increase.
- Contravisory Investment Management's biggest Q3 2014 reduction was Gilead Sciences, cutting an estimated $1.91M.
- Contravisory Investment Management fully exited Paramount Global Class B in Q3 2014, selling an estimated $17.2M.
- Contravisory Investment Management's ten largest holdings make up 33% of its $480M portfolio in Q3 2014.
- Contravisory Investment Management opened 38 new positions and closed 37 in Q3 2014.
- Contravisory Investment Management's portfolio value fell 5.3% quarter-over-quarter to $480M.
Based on Contravisory Investment Management's 13F filing for Q3 2014, filed 10 Oct 2014.